Vor Biopharma (VOR) Income from Continuing Operations (2020 - 2026)

Vor Biopharma (VOR) has 7 years of Income from Continuing Operations data on file, last reported at 31335000.0 in Q1 2026.

• On a quarterly basis, Income from Continuing Operations rose 8.31% year-over-year to 31335000.0 in Q1 2026; TTM through Mar 2026 was 374965000.0, a 203.16% decrease from a year earlier, with the FY2025 full-year figure at 598495000.0, down 133.68% from the prior year.
• Income from Continuing Operations for Q1 2026 stood at 31335000.0, up from 33275000.0 in the prior quarter.
• Over the last five years, Income from Continuing Operations for VOR reached as high as 22985000.0 in Q2 2022 and fell as low as 283943000.0 in Q2 2025.
• Historically, Income from Continuing Operations has averaged 44215647.06 across 5 years, with a median of 29977000.0 in 2023.
• Across the five-year window, Income from Continuing Operations jumped 89.35% in 2022 and tumbled 917.39% in 2025, its largest moves.
• Year by year, Income from Continuing Operations stood at 26627000.0 in 2022, then dropped by 7.62% to 28656000.0 in 2023, then declined by 13.05% to 32397000.0 in 2024, then dropped by 2.71% to 33275000.0 in 2025, then gained by 5.83% to 31335000.0 in 2026.
• Per Business Quant data, the three most recent Income from Continuing Operations figures were 31335000.0 in Q1 2026, 33275000.0 in Q4 2025, and 26412000.0 in Q3 2025.